The latest price target for Pasithea Therapeutics (NASDAQ:KTTA) was reported by EF Hutton on July 10, 2023. The analyst firm set a price target for $2.00 expecting KTTA to fall to within 12 months (a possible -24.53% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Pasithea Therapeutics (NASDAQ:KTTA) was provided by EF Hutton, and Pasithea Therapeutics reiterated their buy rating.

There is no last upgrade for Pasithea Therapeutics

There is no last downgrade for Pasithea Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pasithea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pasithea Therapeutics was filed on July 10, 2023 so you should expect the next rating to be made available sometime around July 10, 2024.

While ratings are subjective and will change, the latest Pasithea Therapeutics (KTTA) rating was a reiterated with a price target of $0.00 to $2.00. The current price Pasithea Therapeutics (KTTA) is trading at is $2.65, which is out of the analyst’s predicted range.